Holtzmann J, Polosan M, Baro P, Bougerol T
Département de Psychiatrie, Hôpital Sud, Centre Hospitalier Universitaire de Grenoble, avenue de Kimberley, BP 338, 38434 Echirolles.
Encephale. 2007 Sep;33(4 Pt 1):572-8. doi: 10.1016/s0013-7006(07)92055-2.
Electroconvulsive therapy (ECT) is one of the most effective treatments for depression. Although it has been used for over 60 years, the basis for its therapeutic effect is still unknown. Structural plasticity within the nervous system such as neurogenesis or mossy fiber sprouting could be involved in the mechanisms underlying the antidepressant effect of several pharmacological antidepressants. But what is the mechanism underlying ECT?
Several methodological issues using magnetic resonance spectroscopy for humans and rats found changes in neuronal metabolism during ECT. The levels of N-Acetyl-Aspartate, an amino acid exclusively located in neurons, are increased after ECT; choline, which is believed to represent membrane turn-over, increases as well. These results are in good agreement with ECT induced structural plasticity. Electroconvulsive seizures (ECS), an animal model of ECT, can enhance neurogenesis, particularly in the hippocampal dentate gyrus. A series of seizures increases neurogenesis more than a single shock. In the glucocorticoid paradigm of depression, ECS can increase hippocampal neurogenesis. This suggests that induction of neurogenesis might be implicated in the antidepressant mechanism of ECT.
As suggested by previous studies, Brain Derived Neurotrophic Factor (BDNF) is supposed to play a critical role in the action of antidepressants through neuronal plasticity. ECS increases the expression of BDNF. The BDNF gene has four differentially regulated promoters that generate four transcript forms. Studying the regulation of these transcript forms by diverse classes of antidepressant therapeutics, including ECS, suggests that diverse signalling mechanisms may be recruited to regulate BDNF transcripts. Moreover, for ECS, these signalling mechanisms seem to differ from those recruited by excitotoxic cell death phenomena, such as neuronal damage or epileptic seizure models.
These results indicate the participation of neuronal plasticity to help account for the antidepressant effect of ECT. However, this relationship is currently not clearly defined, particularly in terms of causality, and will require future studies to unravel it.
电休克疗法(ECT)是治疗抑郁症最有效的方法之一。尽管它已被使用了60多年,但其治疗效果的基础仍然未知。神经系统内的结构可塑性,如神经发生或苔藓纤维发芽,可能参与了几种抗抑郁药物抗抑郁作用的潜在机制。但ECT的潜在机制是什么呢?
多项针对人类和大鼠的磁共振波谱研究方法发现,ECT期间神经元代谢发生了变化。N-乙酰天门冬氨酸(一种仅存在于神经元中的氨基酸)的水平在ECT后升高;胆碱被认为代表膜更新,其水平也升高。这些结果与ECT诱导的结构可塑性高度一致。电惊厥发作(ECS)是ECT的动物模型,可增强神经发生,尤其是在海马齿状回。一系列发作比单次电击更能增加神经发生。在抑郁症的糖皮质激素模型中,ECS可增加海马神经发生。这表明神经发生的诱导可能与ECT的抗抑郁机制有关。
如先前研究所表明的,脑源性神经营养因子(BDNF)被认为在抗抑郁药物通过神经元可塑性发挥作用的过程中起关键作用。ECS可增加BDNF的表达。BDNF基因有四个受不同调节的启动子,产生四种转录形式。研究包括ECS在内的各类抗抑郁治疗药物对这些转录形式的调节表明,可能会募集不同的信号机制来调节BDNF转录本。此外,对于ECS,这些信号机制似乎与兴奋性毒性细胞死亡现象(如神经元损伤或癫痫发作模型)所募集的机制不同。
这些结果表明神经元可塑性参与其中,有助于解释ECT的抗抑郁作用。然而,目前这种关系尚未明确界定,尤其是在因果关系方面,需要未来的研究来阐明。